COVID-19 Vaccine Resources |
Vaccine Interchangeability |
|
As per NACI, either an mRNA or protein subunit COVID-19 vaccine can be used in unvaccinated or previously vaccinated individuals who do not have contraindications to the vaccine. mRNA XBB COVID-19 vaccines are authorized for those six months of age and older and Novavax XBB is authorized for 12 years of age and older. Regardless of which product is offered to start a vaccine series, the previous dose should be counted, and the series need not be restarted. There are no data available on the interchangeability of Novavax XBB with other COVID-19 vaccines to complete the vaccination series. |
Pregnancy/Breastfeeding |
|
COVID-19 vaccination during pregnancy is effective at protecting pregnant individuals against severe COVID-19 disease, hospitalization, and ICU admission from COVID-19 infection, as well as intubation and mortality in those with severe disease. Pregnant or breastfeeding individuals should receive all recommended COVID-19 vaccine doses as soon as they are able. In addition to protecting the pregnant individual, the benefits of immunization during pregnancy for the fetus and infants have also been well-documented. Protective antibodies are transferred to the fetus transplacentally, resulting in increased protection for the infant during the early postnatal period when they are not yet eligible for vaccination (CIG, 2023). Recommendations for vaccination during pregnancy and/or breastfeeding:
There have been no serious safety concerns with receiving an mRNA COVID-19 vaccination during pregnancy or lactation. Pregnant or breastfeeding individuals experience the same rates of expected local and systemic adverse events as individuals who are not pregnant and/or breastfeeding. Vaccination during pregnancy does not increase risk of miscarriage, stillbirth, low birth weight, preterm birth, NICU admission or other adverse pregnancy/birth outcomes. Similarly, studies have not found any negative impact of vaccination on the child being fed human milk or on milk production or excretion. In fact, protective antibodies transferred to the child via breast milk, can help protect the infant during the early postnatal period when they are not yet eligible for vaccination. |
Addressing Vaccine Hesitancy |
|
Emerging Research |
|
Emerging Topics: Synopsis of COVID-19 Key Research Articles (Public Health Ontario) COVID-19 epidemiology update: Summary (Government of Canada) |
COVID-19 Serology |
